- To build the second oligonucleotide manufacturing plant for an expansion of production facilities and to preoccupy the rapidly growing oligonucleotide therapeutics market.
- Will invest in total $126 million at Banwol campus located in Ansan until 2025.
[Source]
https://www.biospectrumasia.com/news/40/19417/korea-based-st-pharm-takes-leap-towards-worlds-largest-oligonucleotide-cdmo.html